Risk of Death or Reinfarction Associated With the Use of Selective Cyclooxygenase-2 Inhibitors and Nonselective Nonsteroidal Antiinflammatory Drugs After Acute Myocardial Infarction
Top Cited Papers
- 27 June 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 113 (25) , 2906-2913
- https://doi.org/10.1161/circulationaha.106.616219
Abstract
Background— The selective cyclooxygenase-2 (COX-2) inhibitors and other nonselective nonsteroidal antiinflammatory drugs (NSAIDs) have been associated with increased cardiovascular risk, but the risk in patients with established cardiovascular disease is unknown. We analyzed the risk of rehospitalization for acute myocardial infarction (MI) and death related to the use of NSAIDs including selective COX-2 inhibitors in patients with prior MI. Methods and Results— All patients with first-time MI between 1995 and 2002 as well as all prescription claims for NSAIDs after discharge were identified from nationwide Danish administrative registers. The risk of death and rehospitalization for MI associated with the use of selective COX-2 inhibitors and nonselective NSAIDs was studied with the use of multivariable proportional hazards models and case-crossover analysis. A total of 58 432 patients were discharged alive and included in the study; 9773 experienced rehospitalization for MI, and 16 573 died. A total of 5...Keywords
This publication has 36 references indexed in Scilit:
- Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysisBMJ, 2005
- Risk of Hospitalization for Myocardial Infarction Among Users of Rofecoxib, Celecoxib, and Other NSAIDsArchives of internal medicine (1960), 2005
- The Risk for Myocardial Infarction with Cyclooxygenase-2 Inhibitors: A Population Study of Elderly AdultsAnnals of Internal Medicine, 2005
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialNew England Journal of Medicine, 2005
- Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma PreventionNew England Journal of Medicine, 2005
- Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control studyThe Lancet, 2005
- Patients Exposed to Rofecoxib and Celecoxib Have Different Odds of Nonfatal Myocardial InfarctionAnnals of Internal Medicine, 2005
- Risk of Cardiovascular Events Associated With Selective COX-2 InhibitorsJAMA, 2001
- Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000